AstraZeneca PLC Files July 2025 6-K Report

TL;DR

AZN filed its July 6-K, standard foreign issuer report.

AI Summary

AstraZeneca PLC filed a Form 6-K on July 1, 2025, reporting for the month of July 2025. The filing indicates that AstraZeneca is a foreign issuer and files annual reports under Form 20-F. The company's principal executive offices are located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.

Why It Matters

This filing serves as an update for investors and regulatory bodies regarding AstraZeneca's ongoing reporting obligations as a foreign issuer.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign issuer and does not contain new material financial or operational information.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report
• 001-11960 (company) — Commission File Number
• 1 Francis Crick Avenue (company) — Company business address
• Cambridge Biomedical Campus (company) — Company business address
• CB2 0AA (company) — Company business address postal code
• United Kingdom (company) — Company country of operation

FAQ

From the Filing

0001654954-25-007604.txt : 20250701 0001654954-25-007604.hdr.sgml : 20250701 20250701113402 ACCESSION NUMBER: 0001654954-25-007604 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250701 FILED AS OF DATE: 20250701 DATE AS OF CHANGE: 20250701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251094864 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a0819p.htm TOTAL VOTING RIGHTS a0819p FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of July 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________               AstraZeneca PLC   INDEX TO EXHIBITS     1. Total Voting Rights     1 July 2025     Transparency Directive Voting rights and capital   The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 June 2025 the issued share capital of AstraZeneca PLC with voting rights is 1,550,670,668 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,670,668.   The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.   AstraZeneca   AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit  astrazeneca.com  and follow the Company on social media  @AstraZeneca       Contacts For details on how to contact the Investor Relations Team, please click  here . For Media contacts, click  here .       Matthew Bowden Company Secretary